[p53 antibodies assay in Syrian mamma carcinoma patients]

The aim of this study was to assay of p53 antibodies in the serum of Syrian breast cancer patients, and to correlate these results with various clinical parameters. We also wanted to assess the prognostic significance of these antibodies in treatment monitoring and recurrence in patients. Serum of 60 patients of breast cancer, 35 patients of benign mass and 35 of control were analyzed using Enzyme linked immunoadsorbent assay ELISA. Eight of sixty breast cancer patients was positive for p53 antibodies [13.3%], one patient of benign mass patients were positive for p53 antibodies [2.9%] and p35 antibodies weren't detected in control group. The difference was statistically significant [p<0.05]. We observed an inverse relationship between the presence of p53 antibodies and the age of the patients. We found no significant association between the presence of p53 antibodies and tumor size. p53 antibodies were higher in patients with metastasis to axillary lymph nodes and advanced stages, but the difference was not statistically significant [p>0.05]. When we followed up patients of positive anti-p53 antibodies after surgery, chemotherapy or radiotherapy, there was a decrease in anti-p53 antibodies as a biomarker as well as a prognostic factor for patients with breast cancer

[Tumor suppressor protein p53 autoantibodies assay in colorectal cancer patients]

Mutation of the p53 tumor suppressor gene is the most common genetic alteration in colorectal cancer, and detection of p53 antibodies in serum might be an effective indirect procedure to detect alterations of the p53 gene. This study aimed to detect the presence of p53 antibodies in patient with colorectal cancer, and to study the association between this antibodies and tumor stage, tumor location, gender, age and smoking. We analyzed serum for p53 antibody using Enzyme linked Immune-adsorbent assay in 57 patients of colorectal cancer and 33 patients of benign disease in gastrointestinal [Crohn's Disease, Ulcerative Colitis] and 35 healthy individuals. Eight of seventy five colorectal cancer patients were positive for p53 antibodies [14%], and p53 antibodies weren't detected in patients with benign gastrointestinal diseases, neither in healthy subjects [control group]. The difference was statistically significant [p<0.05]. We found no significant association between the frequency of anti-p53 antibodies and tumor size, tumor location, gender and smoking. However sero-positive patients were older than sero-negative patients. P53 antibodies are a specific tumor marker of colorectal cancer, and there is no association between the frequency of anti p53 antibodies and tumor size, tumor location, gender and smoking